Breakthrough PTSD treatment achieves 68% remission rate in clinical trial

The Quick Take
A newly FDA-cleared PTSD treatment uses personalized brain mapping and magnetic stimulation to target abnormal brain activity, with a clinical trial reporting a 52% reduction in symptoms and 68% remission. Researchers believe the technology could transform PTSD care and pave the way for more precise treatments for other mental health conditions.
Ground Level News gathers headlines from public news feeds. This page shows a short summary only; the full article and all rights belong to Latest Science News -- ScienceDaily.



